While companies selling array-based tests, including CombiMatrix, Arrayit, and Veredus Labs, are keen to make their platforms available to laboratories for identifying the flu strain, the FDA has only given emergency use authorization for a PCR-based test. Moreover, companies that sell flu chips are unlikely to see their technology adopted unless the current swine flu strain mutates, according to some sources.
Over the next year, the company hopes to open three more sequencing labs in partnership with biology researchers, probably in Thailand, Mexico, and France, for which it will provide bioinformatics services through its Houston facility.
Officials from Billerica, Mass.-based Aushon Biosystems and Roslin, UK-based Arrayjet separately told BioArray News this week that, in spite of overall market conditions, they are seeing increasing demand for arrayers from pharmaceutical and biotech companies as well as academics.
Genome Analysis Centre, University of Barcelona, NIAID, Massachusetts Institute of Technology, J. Craig Venter Institute, University of Maryland, SeqWright, Hologic, BioReference Laboratories, GeneDx, University of Michigan, Genomatix Software, NHGRI